Tech Company Inital Public Offerings
Epizyme IPO
Epizyme, operating out of Cambridge, debuted as a public company on 5/31/2013.
Transaction Overview
Company Name
Announced On
5/31/2013
Transaction Type
IPO
Amount
$76,500,000
Proceeds Purpose
Proceeds purposes are on file with company statements at the SEC.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
400 Technology Sq. 4th Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies for cancer patients. The company?s proprietary product platform creates small molecule inhibitors of enzymes known as histone methyltransferases (HMTs).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Bazemore
Chief Financial Officer
Paolo Tombesi
Chief Medical Officer
Shefali Agarwal
Chief Operating Officer
Matthew Ros
VP - General Counsel
John Weidenbruch
VP - Regulatory Affairs
Mark De Rosch
Browse more venture capital transactions:
Prev: 5/31/2013: Panasas venture capital transaction
Next: 5/31/2013: Weotta venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to report on every notable VC transaction. VC investment data records on this site are derived from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs